CTOs on the Move

Q32 Bio

www.q32bio.com

 
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.q32bio.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.999.0232

Executives

Name Title Contact Details
Saul Fink
Chief Technology Officer Profile

Funding

Q32 Bio raised $46M on 05/27/2020
Q32 Bio raised $60M on 10/29/2020

Similar Companies

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tengion

Tengion is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dance Biopharm

Dance Biopharm is a private company focused on developing novel inhaled formulations of medicines to treat diabetes and other serious chronic diseases.

Cerecin

Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat diseases of the brain. Cerecin`s development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of medium-chain triglycerides. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world`s leading manufacturers of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.